Loading stock data…
$1.81+0.13 (+7.74%)
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
INmune Bio Inc. in the Healthcare sector is trading at $1.81 with a market capitalization of $64M. Wall Street consensus targets $7.00 (3 analysts), implying a +286.7% move over the next 12 months. The stock is currently 30% below its 52-week high of $2.60, remaining 10.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.48M↑ | -$5.81M↓ | -$5.47M↑ | -$7.43M↑ | -$8.06M |
| Net Income | -$1.27M↑ | -$5.41M↓ | -$5.26M↑ | -$6.47M↑ | -$24.46M |
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic ma...